Matrix metalloproteinases (MMPs) are zinc endopeptidases that degrade extracellular matrix (ECM) components during normal and pathogenic tissue remodeling.
Introduction
Matrix Metalloproteinases (MMPs) are a large family of Zn 2+ -containing endopeptidases that play a key role in degrading extracellular matrix (ECM) components.
MMP activation has been implicated in physiological and pathological tissue remodeling in multiple contexts, including cancer invasion, inflammation, organ development, angiogenesis and wound healing (1) . The MMP family contains more than 20 members, including collagenases, gelatinases, matrilysins, stromelysins and metalloelastases.
Active MMPs trigger the degradation of ECM components such as collagens, elastin, gelatin, fibronectin, laminin and proteoglycans. In addition, MMP activity induces the processing of several non-ECM proteins including α 1 -antitrypsin, α 2 -macroglobulin, plasminogen, serum amyloid protein A (2) . The MMP activity is regulated at several levels, including gene transcription, cellular secretion, activation of proenzymes, and binding to tissue inhibitors of metalloproteinases (TIMPs). Increasing experimental evidence supports a direct link between elevated MMP activity and diseases that involve enhanced turnover of the ECM, such as atherosclerosis and rheumatoid arthritis (3) .
Enhanced expression of several MMPs, including MMP-9 and MMP-1, has been documented in both murine and human atherosclerotic lesions. Macrophages are a primary source of MMP expression, and their elaboration of these enzymes is believed to contribute to smooth muscle cell (SMC) migration, neointima formation, and plaque rupture (4) . MMP-9 degrades vessel wall collagens, elastin, and vitronectin (5) , and matrix degradation in atherosclerotic plaques can be localized to areas of macrophage accumulation (6) . It has also been demonstrated that MMP-9 is transiently upregulated in experimental models of vascular injury and that its activity contributes to the development of intimal lesions by promoting SMC migration (7) . Previous work has shown that macrophage MMP-9 expression is induced by pro-inflammatory stimuli including cytokines, chemokines and bacterial wall components (8) (9) (10) (11) ).
Met hod s Reagents and plasmids
GW3965 and T0901317 were provided by Tim Willson and Jon Collins (GlaxoSmithKline). Ligands were dissolved in dimethyl sulfoxide prior to use in cell culture. LPS from Salmonella typhimurium was purchased from Sigma. TNF-α, IFN-γ and IL-1β were from PeproTech. pCMX expression plasmids for LXRα, LXRβ and RXR have been described (12, 13) . The MMP-9 promoter constructs (-670, -531 and -70) linked to the firefly luciferase gene have been also described (14) .
Cell culture and transfections
Peritoneal macrophages were obtained from thioglycolate-injected mice as described (15) and cultured in RPMI containing 10% fetal bovine serum (FBS). Bone marrow derived macrophages (BMDM) from age-matched WT and LXRαβ-/-mice were prepared as described (16) . Briefly, bone marrow cells extracted from femurs were incubated for 24 h in Dulbecco's modified Eagle's medium (DMEM) supplemented with 15% FBS. After 24h nonadherent cells were collected and grown for 6 days in complete DMEM supplemented with 30% of filtered supernatant from L929 cells expressing M-CSF. On day 6, adherent BMDM were deprived of M-CSF for 24h and cultured in DMEM containing 10% LPDS for another 24h prior any stimulation. RAW 264.7 cells were cultured in DMEM medium containing 10% FBS. For ligand treatments, cells were cultured in RPMI or DMEM medium, supplemented with 5% lipoprotein-deficient serum (LPDS) (Intracel) and receptor ligands for 18 h prior to LPS or cytokine stimulation.
Transient transfections of RAW 264.7 cells were performed in triplicate in 48-well plates. 
Western Blot Analysis
Macrophages were cultured in 10cm dishes at 90% confluence with 5ml of RPMI containing 5% LPDS. After treatment, conditioned media was collected and briefly centrifuged at 500g. Supernatants were collected and protein content was assayed using the Bio-Rad protein reagent. For intracellular proteins, cytosolic and nuclear extracts were prepared as described before (17) . Samples containing equal amounts of protein were boiled in 250 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 2% ß-mercaptoethanol, and size-separated in 8% SDS-PAGE. Proteins were transferred to nitrocellulose and the membrane was blocked overnight 0.01% Tween-20 PBS containing 5% non-fat milk. 
RNA analysis
Total RNA was extracted using Trizol reagent (Life Technologies, Inc). Northern analysis was performed as described (18) . Blots were probed with specific radiolabeled probes for MMP-9, MMP-13 and MMP-12 and normalized using cDNA probe for 36B4.
Probes were obtained by PCR using the following primers: MMP-9 Fwd: 5'-ttaccagcgccagccgacttttg-3'; MMP-9 Rev: 5'cgtcgtcgtcgaaatgggcatc-3'; MMP-13 Fwd: 5'-ggccagaactccccaaccat-3'; MMP-13 Rev: 5'-acccccaccccatacatctgaaagt-3'; MMP-12 Fwd:
5'-ttctttgggctagaagcaactgggc-3'; MMP12 Rev: 5'-gcagcttgaatagcagatgggatgc-3'. Realtime quantitative PCR (TaqMan) analysis was performed using an Applied Biosystems 7700 sequence detector as described (19) . Primer and probe sequences for MMP-9 were:
Forward: 5'-tcaccttcacccgcgtgta3'; reverse: 5'-gtcctccgcgacaccaa-3'; probe: 5'-/56-FAMacccgaagcggacattgtcatccag/3BHQ-1/-3'. All assays were performed in duplicate and cycle thresholds of individual genes were normalized to 36B4. 
Electrophoretic mobility shift assays

Results
We reported previously that administration of a synthetic LXR ligand diminishes lipid accumulation and atherosclerotic lesion formation in murine models (19) . In an effort to better understand the molecular basis of these effects we used Affymetrix oligonucleotide arrays to identify novel LXR regulated genes in macrophages (20, 21) .
These studies led to the identification of MMP-9 as a potential LXR-responsive gene. To Most importantly, in contrast to MMP-9, LXR agonists had no effect on the expression of MMP-12 and MMP-13.
In order to determine whether the inhibitory effect observed with GW3965 and T1317 is actually mediated by LXRs, we performed a series of experiments with macrophages derived from either WT mice or those with target disruptions of the LXRα and/or LXRβ genes. Figure 3A illustrates that the ability of GW3965 to inhibit both basal and LPS-induced expression of MMP-9 is completely abolished in peritoneal macrophages derived from LXRαβ -/-mice. Since GW3965 activates both LXRs, we also used knockout cells to determine whether the inhibitory effect of this ligand was mediated by LXRα, LXRβ or both. Peritoneal macrophages from mice carrying a single disruption of either LXRα or LXRβ exhibited the same pattern of MMP-9 inhibition as WT macrophages after LXR agonist treatment ( Figure 3B ). Thus, both LXRs are competent to mediate the inhibitory effect. We also confirmed these results with BMDM challenged with LPS for 6 and 18h ( Figure 3C ). GW3965 reduced expression of MMP-9
at both time points in WT cells, whereas no effect was observed in LXRαβ -/-cells. In contrast to MMP-9 expression, MMP-13 expression was not altered by LXR ligand and did not differ between LXR genotypes. To determine the effect of LXR activation on MMP-9 protein expression, we analyzed conditioned medium for secreted protein as described previously (14, 24, 28, 29) . Inhibition of MMP-9 mRNA expression by LXR agonist correlated with reduced levels of protein expression as revealed by western blot analysis of conditioned media from WT BMDM treated for 24h with LPS, TNFα or IL-1β ( Figure 3D ). No change in MMP-9 protein expression was observed in LXRαβ -/-macrophages.
We also used WT and LXR null BMDM to characterize the effects of LXR agonists on TNFα-mediated induction of MMP-9 expression. Using TNFα as an inducer, we found that increasing concentrations of this cytokine (0.1 to 100 ng/ml) stimulated MMP-9 expression in both LXR WT and null cells. However, the genetic absence of LXR led to a significant increase in both basal and stimulus-dependent expression ( Figure 4A ). This observation suggests that LXR null cells are more responsive than WT cells to TNFα stimulation, at least with respect to MMP-9 expression. It is also notable that the ability of LXR agonists to block MMP-9 expression was evident even in the presence of very high concentrations (100ng/ml) of TNFα. We also performed a time-course experiment in order to assess the persistence of the LXR inhibitory effects in the face of sustained inflammatory signals. Expression of MMP-9
mRNA in response to a moderate dose of TNFα (10 ng/ml) steadily increased over time (2h to 24h, Figure 4B ). Longer periods of time were also evaluated but no further increase was observed beyond 24 h (not shown). At all time points, the presence of LPS and/or GW3965 as indicated in Figure 5 . As expected, a ten fold increase in MMP-9
promoter activity was observed in response to LPS. Pretreatment with GW3965 led to a moderate reduction in luciferase activity in the presence of control vector, whereas a marked suppression was observed when LXRα/RXR expression vectors were cotransfected ( Figure 5A ). To localize the regions important for mediating LXR-dependent repression, we analyzed truncated MMP-9 promoter constructs. Macrophages transfected with a construct containing sequences from -531 bp to + 30 bp of the promoter, which lacks the NF-κB binding site, showed reduced luciferase activity after LPS treatment ( Figure 5B) . However, the presence of the AP-1 site in this construct still permitted a three fold increase in luciferase activity. Remarkably, expression of this construct was not inhibited by GW3965 treatment even when LXRα was over-expressed. No significant luciferase activity was observed with a construct containing the minimal promoter of MMP-9 (-73 bp, Figure 5C ). These results indicate that the ability of LXR to inhibit the MMP-9 promoter requires the NF-κB binding site.
The results of Figure 5 strongly suggest that LXR activation inhibits MMP-9 expression through antagonism of the NF-κB signaling pathway. To investigate potential mechanisms for this effect we treated WT peritoneal macrophages with GW3965 and then activated them with 200 ng/ml of LPS. Cells were harvested at different time points and soluble extracts were collected. Cytosolic proteins were size separated and the levels of I-κBα protein were analyzed by Western blotting. I-κBα is degraded within the first 30 min of stimulation with LPS and then rapidly re-synthesized to provide negative feedback control and limit NF-κB activation. Figure 6 demonstrates that the upstream signaling pathway leading to I-κBα degradation is not altered in response to LXR activation. I-κBα is degraded to the same extent with or without GW3965 after 30 min of LPS challenge in both WT and LXRαβ -/-macrophages. We also analyzed the expression levels of IKK-1, one of the catalytic subunits responsible for I-κBα phosphorylation. Again, no significant changes were observed after GW3965 treatment in either genotype ( Figure 6 ). Taken together, these data indicate that LXR-mediated inhibition of MMP-9 expression is downstream of I-κBα phosphorylation-degradation.
To further investigate the mechanism of LXR effects on the NF-κB pathway, we These observations indicate that the signaling pathways that lead to NF-κB activation are not significantly impaired by LXR and suggest that LXR agonists may exert their effects downstream of NF-κB binding to DNA.
Discussion
The Liver X receptors (LXRs) are members of the nuclear receptor superfamily activated by oxysterols and play an important role in maintaining lipid and lipoprotein homeostasis. In macrophages, where both LXRs are highly expressed, these receptors control the cholesterol efflux pathway through the regulation of target genes including ABCA1 and apolipoprotein E (12, (31) (32) (33) . The synthetic LXR ligand GW3965 reduces the development of atherosclerosis in LDL receptor and apoE deficient mice (19) .
Conversely, LXRαβ null mice exhibit foam cell accumulation in multiple tissues, including aorta, lung, spleen and brain (19, 34, 35) . Transplantation of LXR deficient bone marrow into LDLR and apoE knockout mice results in increased atherosclerosis, demonstrating the relevance of macrophage LXR activity in the prevention of atherosclerosis (34) . In an effort to better understand the molecular basis of these effects we have endeavored to identify novel LXR target genes in macrophages. In the present study we have shown that ligand activation of LXRs in macrophages inhibits both basal and cytokine inducible expression of the MMP-9 gene. These observations support a role for LXRs in the regulation of macrophage inflammatory responses.
The relationship between chronic inflammation and atherosclerosis is clearly evident. Components and mediators of the immune system, including macrophages, T cells, complement and inflammatory cytokines are key players in the atherogenic process (36) (37) (38) . MMP-9 is highly expressed by macrophages and smooth muscle cells in areas of atheroma formation and participates in the degradation of ECM components at the shoulder regions of atherosclerotic lesions (7, 26, 39) . This proteolytic activity is proposed to lead to plaque instability and ultimately to plaque rupture and resulting thrombus formation. Targeted disruption of the MMP-9 gene results in decreased SMC migration in vitro and in vivo and reduces intimal hyperplasia (29) . In addition, administration of broad MMP inhibitors in mouse models results in reduced progression of atherosclerotic lesions and neointima formation (26, 40) . However, the availability of specific MMP inhibitors is still very limited. There is therefore considerable interest in identifying alternative mechanisms by which excessive MMP production can be limited. Activated NF-κB can be detected in atherosclerotic lesions, mainly within macrophages and smooth muscle cells, whereas little NF-κB activation is detected in healthy vessels (43) . Thus, the enhanced expression of inflammatory genes such as MMP-9 during the development of atherosclerosis can be ascribed to activation of these transcription factors.
Our results suggest that LXR activation leads to an impairment of NF-κB action on the MMP-9 promoter. Unfortunately, the mechanism underlying this effect is not yet clear.
We found that the upstream signaling pathway controlling NF-κB activation is not affected by LXR. LPS-induced I-κB degradation and nuclear translocation of NF-κB were not altered by LXR ligands and were not different in WT and LXR null macrophages. These observations suggest that LXR agonists may exert their effects downstream of NF-κB binding to DNA. More research will be needed to determine the mechanism underlying LXR suppressive effects.
Interference with NF-κB signaling has been proposed by other authors to explain the inhibitory effects of IFNs on MMP-9 expression in several cancer cell types. IFNs inhibit MMP-9 expression through activation of IRF-1 which blocks NF-κB activity without affecting I-κB degradation nor NF-κB nuclear translocation (14, 24) . Normalized luciferase activity
Castrillo Figure 5 
